IOncology

Investigator-initiated trials (IITs) refer to clinical research initiated by investigators, conducted in healthcare institutions, and aimed at studying disease diagnosis, treatment, rehabilitation, prognosis, etiology, prevention, and health maintenance. Unlike industry-sponsored trials, IITs are not intended for drug or medical device registration. In recent years, IITs have become an essential part of clinical research, providing critical data and insights for drug development in China. However, the rapid increase in IITs has underscored the need for enhanced management and standardization.

The 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) concluded successfully on November 17. Following the strategic framework of "collaborative integration" in disciplinary development, the conference established dedicated sessions on tumor rehabilitation, health education, cancer prevention, and screening. These sessions offered comprehensive and multidimensional insights into new perspectives, technologies, and concepts for the full-cycle management of oncology, spanning prevention, screening, diagnosis, treatment, and rehabilitation.

At the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), Dr. Xinping Cao from Sun Yat-sen University Cancer Center presented a comprehensive lecture titled “Advances in Systemic Therapy for Cervical Cancer.” Below is a summary of the key highlights.

Breast cancer not only threatens patients' lives but also imposes a heavy psychological burden on women. As the number of breast cancer cases continues to rise, its rehabilitation is gaining increasing attention from society. How to effectively promote comprehensive recovery for breast cancer patients has become an important issue in the medical field. During the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), Oncology Frontier interviewed Dr. Hong Liu, Chair of the Breast Cancer Integrated Rehabilitation Committee of the Chinese Anti-Cancer Association and a leading expert at Tianjin Medical University Cancer Institute and Hospital. Professor Liu discussed the importance of psychological rehabilitation for breast cancer patients, prospects for the development of the rehabilitation field, applications of new technologies and methods, and the significance of multidisciplinary collaboration. Drawing on her extensive clinical experience, Professor Liu shed light on new trends in breast cancer rehabilitation, offering hope for patients.

On November 23rd, Dr. Tianshu Liu's team from Zhongshan Hospital published a study titled "Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial" in JNCI Cancer Spectrum(IF=3.4). The PRESERVE 1 trial sheds light on trilaciclib's potential to reduce chemotherapy-related toxicity in mCRC. While its efficacy in mitigating myelosuppression is evident, the antitumor results are concerning. Further studies are needed to explore the balance between toxicity reduction and efficacy, and to determine trilaciclib's optimal use in cancer treatment.

EGFR mutations are among the most common genetic abnormalities in non-squamous non-small cell lung cancer (NSCLC), and EGFR-TKIs have become the standard first-line treatment for advanced EGFR-mutant NSCLC. Despite significant advancements across three generations of EGFR-TKIs, resistance remains unavoidable. Post-resistance treatment options for EGFR-TKI patients, particularly those facing complex third-generation resistance mechanisms, are limited.

At the 2024 CCHIO Lung Tumor Integrated Rehabilitation Session, Dr. Dingzhi Huang from Tianjin Medical University Cancer Institute and Hospital delivered a presentation titled “Advances in SCLC Treatment.” Below is a comprehensive summary of the key highlights.

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has rapidly advanced in the treatment of lung cancer in recent years. However, challenges remain, such as limited efficacy with monotherapy and increased side effects with combination therapies. Multi-targeted combination therapies represent a potential avenue for advancing immunotherapy. Among them, bispecific antibodies (BsAbs), which simultaneously target two different antigens or epitopes, have emerged as a focus of attention for their ability to enhance the immune system's recognition and destruction of tumor cells.

From November 22 to 24, 2024, the CSCO Gastric Cancer Committee Annual Meeting convened in Beijing, gathering leading experts to discuss the latest advancements, challenges, and opportunities in gastric cancer management. Dr. Ting Deng from Tianjin Medical University Cancer Institute and Hospital delivered a keynote presentation titled "ADC Combination Strategies for Gastric Cancer: Directions and Advances."